Detalhe da pesquisa
1.
Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumors.
J Immunother Cancer
; 9(2)2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33608377
2.
Targeting Notch signaling with a Notch2/Notch3 antagonist (tarextumab) inhibits tumor growth and decreases tumor-initiating cell frequency.
Clin Cancer Res
; 21(9): 2084-95, 2015 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-25934888